Delivering Pharmaceutical Innovations Domestically and Globally
Toward Realizing the JPMA's Vision for 2035We are moving forward with our activities centered on the three pillars of Innovation, Access, and Trust.
Consistently produce innovations to benefit health spans and the economy
-
Drug Evaluation Committee
We have posted the presentation slides titled “How Pharmaceutical Companies Evaluate Adverse Event Reports from Healthcare Facilities and Translate Them into Safety Measures—The Journey of a Single Report to a Safety Measure That Protects Patients” (August 22, 2026, 56th Academic Conference of the Kanto Block, Japan Hospital Pharmacists Association).
-
Biopharmaceutical Committee R & D Committee The Office of Pharmaceutical Industry Research Event Reports
Announced at BioJapan 2026! Co-creation to Strengthen Japan’s Drug Discovery Ecosystem
Bring innovative new drugs to the public more quickly to enhance health security
-
Quality & Technology Committee
We have posted the request regarding the classification and naming of mini-tablet dosage forms, as well as the responses from the Japanese Pharmacopoeia Draft Review Committee and the Formulation Committee.
-
Distribution Improvement Committee
We have posted the industry-standard manual, “List of Frequently Asked Questions Regarding the 8th System Update of JD-NET.”
Commit to ethical conduct and transparency to foster trust in the pharma industry
-
Latest Issue of the JPMA Newsletter Featuring a special section on “TOWN HALL MEETING” and coverage of various JPMA activities.
-
Event Report: Updated October 28 Report on the “Side Event Held in New York, U.S., During the 81st Session of the United Nations Assembly (UNGA)”
-
Scientific and Practical Requirements for Drug Candidates Sought by Companies ~Regarding Provisions in the TPP~
-
Regarding JPMA’s Vision for 2035 and JPMA’s Policy Proposals for 2025 Announced February 26, 2025
-
“DATA BOOK 2026” has been released.
Update Information
-
Quality & Technology Committee
We have posted the request regarding the classification and naming of mini-tablet dosage forms, as well as the responses from the Japanese Pharmacopoeia Draft Review Committee and the Formulation Committee.
-
Announcements Public Affairs Committee
We have published the “JPMA Newsletter, November 2026 Issue No. 231.”
-
Distribution Improvement Committee
We have posted the industry-standard manual, “List of Frequently Asked Questions Regarding the 8th System Update of JD-NET.”
-
Announcements
Apology and Notice Regarding the Potential Leakage of Email Addresses Due to Unauthorized Access at Our Email Distribution Service Provider
-
International Affairs Committee Event Reports
Report on the “Side Event Held in New York, U.S., During the 81st Session of the United Nations Assembly (UNGA)”
-
Drug Evaluation Committee
We have posted the presentation slides titled “How Pharmaceutical Companies Evaluate Adverse Event Reports from Healthcare Facilities and Translate Them into Safety Measures—The Journey of a Single Report to a Safety Measure That Protects Patients” (August 22, 2026, 56th Academic Conference of the Kanto Block, Japan Hospital Pharmacists Association).
-
Announcements Public Affairs Committee
We have published the “JPMA Newsletter, November 2026 Issue No. 231.”
-
Announcements
Apology and Notice Regarding the Potential Leakage of Email Addresses Due to Unauthorized Access at Our Email Distribution Service Provider
-
Press Releases Code Compliance Committee
Announcement Regarding the “JPMA Code of Practice: Month to Promote Understanding of the JPMA Code”
-
Press Releases
Three Pharmaceutical Associations from Japan, the U.S., and Europe
Joint Statement on the Proposal to Expand the Cost-Effectiveness Evaluation System -
Press Releases Announcements
The Japan Pharmaceutical Manufacturers Association to Transition to a General Incorporated Association Effective October 1, 2026
— Turning Change and Challenges into Strength. Expanding the Circle of Co-creation. — -
Announcements Event Reports
Public and Private Sectors Jointly Highlight the Evolution of the Japanese Market and Clinical Trial Environment at “BIO International Convention 2026”
-
Quality & Technology Committee
We have posted the request regarding the classification and naming of mini-tablet dosage forms, as well as the responses from the Japanese Pharmacopoeia Draft Review Committee and the Formulation Committee.
-
Announcements Public Affairs Committee
We have published the “JPMA Newsletter, November 2026 Issue No. 231.”
-
Distribution Improvement Committee
We have posted the industry-standard manual, “List of Frequently Asked Questions Regarding the 8th System Update of JD-NET.”
-
International Affairs Committee Event Reports
Report on the “Side Event Held in New York, U.S., During the 81st Session of the United Nations Assembly (UNGA)”
-
Drug Evaluation Committee
We have posted the presentation slides titled “How Pharmaceutical Companies Evaluate Adverse Event Reports from Healthcare Facilities and Translate Them into Safety Measures—The Journey of a Single Report to a Safety Measure That Protects Patients” (August 22, 2026, 56th Academic Conference of the Kanto Block, Japan Hospital Pharmacists Association).
-
Biopharmaceutical Committee R & D Committee The Office of Pharmaceutical Industry Research Event Reports
Announced at BioJapan 2026! Co-creation to Strengthen Japan’s Drug Discovery Ecosystem
-
International Affairs Committee Event Reports
Report on the “Side Event Held in New York, U.S., During the 81st Session of the United Nations Assembly (UNGA)”
-
Biopharmaceutical Committee R & D Committee The Office of Pharmaceutical Industry Research Event Reports
Announced at BioJapan 2026! Co-creation to Strengthen Japan’s Drug Discovery Ecosystem
-
Public Affairs Committee Event Reports
Summer 2026: Junior High and High School Girls Head to the Front Lines of Drug Discovery! ~Report on the “Girls Meet STEM” Summer Tour~
-
Quality & Technology Committee Event Reports
We have posted the report on the “FY 2026 (53rd) GMP Case Study Seminar.”
-
Code Compliance Committee Event Reports
We held the “FY 2026 Meeting of Compliance Management Officers and Practitioners.”
-
Regulatory Affairs Committee Event Reports
We have posted a report on our participation in the “16th Annual Conference of the Society for Regulatory Science.”
About JPMA
Under the JPMA Board of Directors, 12 committees composed of member companies and 6 specialized organizations, including the Office of Pharmaceutical Industry Research (OPIR) which functions as a think tank, carry out a wide range of initiatives. These activities aim to establish a robust drug discovery ecosystem for the development of innovative pharmaceuticals, ensure compliance with regulatory frameworks such as the Pharmaceuticals and Medical Devices Act, and build trust with key stakeholders.
Each committee and specialized body bring together a diverse pool of talent - from young professionals to experienced experts - working across organizational boundaries. Through mutual collaboration and constructive exchange, they advance pharmaceutical innovation, promote the appropriate use of medicines, enhance transparency in distribution, foster international cooperation, and formulate policy proposals. In addition, JPMA conducts various surveys and research projects to address industry-wide challenges. By working closely with government authorities, patient advocacy groups, and other relevant organizations, JPMA supports the sound and sustainable development of the pharmaceutical industry.
JPMA's Vision
Consistently produce innovations to benefit health spans and the economy
- Pharmaceutical innovations
- Leading-edge scientific technology
- Pharmaceutical manufacturing technology
- Domestic manufacturing infrastructure
- Making Japan a science and technology powerhouse
- Fostering highly skilled talent
- PPI/E
- Drug discovery that involves patients and the public
- Co-creation
- Drug discovery ecosystem
- Job creation
- Extending health spans
- Well being
- Pharma as a core industry
- Economic growth
Bring innovative new drugs to the public more quickly to enhance health security
- A social security system that gives patients swift access to “the latest treatments” and stable access to “global-standard treatments”
- Positive investment cycle
- Building an attractive domestic market
- Drug pricing that properly factors in the worth of innovation
- Health security for Japan
Commit to ethical conduct and transparency to foster trust in the pharma industry
- Sustainable Development Goal 3 (Ensure healthy lives and promote well-being for all at all ages)
- Overcome the social challenges raised by Japan’s aging population
- Ethical soundness, code of behavior, and transparency
- Boost public literacy in health and medicine
- Social significance of pharmaceuticals and the pharma industry
- Encourage the public and younger people to enter the pharma industry
- Climate change
- Environmental issues
Member Companies
JPMA has 68 research-and-development-oriented pharmaceutical companies as members (as of October 1, 2026).
